Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.49 |
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.33 |
| ▸ | POLQ | O75417 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493659 | 1.00 | TACR1 (0.49) | TACR1GPBAR1NOTUMCCR2DDR1 | |
| SCHEMBL4264358 | 0.93 | TACR1 (0.57) | TACR1GPBAR1CCR2 | |
| SCHEMBL493651 | 0.91 | TACR1 (0.48) | TACR1GPBAR1NOTUMCCR2DDR1 | |
| SCHEMBL3766497 | 0.91 | TACR1 (0.48) | TACR1GPBAR1NOTUMCCR2DDR1 | |
| SCHEMBL3226841 | 0.90 | TACR1 (0.37) | TACR1HDAC6 | |
| SCHEMBL6002099 | 0.90 | TACR1 (0.37) | TACR1HDAC6 | |
| SCHEMBL10019606 | 0.89 | TACR1 (0.50) | TACR1GPBAR1CCR2 | |
| SCHEMBL5327531 | 0.88 | TACR1 (0.49) | TACR1GPBAR1CCR2DDR1 | |
| SCHEMBL5435321 | 0.88 | TACR1 (0.49) | TACR1GPBAR1CCR2DDR1 | |
| SCHEMBL14136104 | 0.87 | TACR1 (0.48) | TACR1GPBAR1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940845-B1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | ALBIREO AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-8288370-B2 | Substituted azetidine compounds of formula (I) useful in the treatment of functional gastrointestinal disorders, IBS, and functional dyspepsia | ALBIREO AB (SE) | 2012-10-16 | — | — | US | disclosed |
| US-8288370-B2 | Substituted azetidine compounds of formula (I) useful in the treatment of functional gastrointestinal disorders, IBS, and functional dyspepsia | ALBIREO AB (SE) | 2012-10-16 | — | — | US | disclosed |
| US-20100311713-A1 | Novel Azetidine Compounds Useful in the Treatment of Functional Gastrointestinal Disorders, Ibs and Functional Dyspepsia | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | disclosed |
| US-20100311713-A1 | Novel Azetidine Compounds Useful in the Treatment of Functional Gastrointestinal Disorders, Ibs and Functional Dyspepsia | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | disclosed |
| EP-2024354-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO]-3- (PHENYL) BUTYL]AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | Albireo AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008118092-A1 | MALEATE SALT OF 3-BROMO-N-{ (2S) -2- (4-F LUOROPHENYL) -4- [3- (4-ACETYLPIPERAZIN-1-YL) AZETIDIN-1-YL] BUTYL} -METHYL-5- (TRIFLUOROMETHYL)BENZAMIDE FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ALBIREO AB (SE) | 2008-10-02 | — | — | WO | disclosed |
| EP-1940845-A1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | Astra Zeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2008076042-A1 | AZETIDINPIPERAZINE DERIVATIVES THAT ARE NEUROKININ (NK) RECEPTOR ANTAGONISTS AND THEIR USE. | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007136324-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO] -3- (PHENYL) BUTYL] AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 1 | ALBIREO AB (SE) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007037743-A1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007037743-A1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007037742-A1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311713-A1 | Novel Azetidine Compounds Useful in the Treatment of Functional Gastrointestinal Disorders, Ibs and Functional Dyspepsia | NISCH, BDKRB2, VIP | TACR1 6/4885GPBAR1 186/4885NOTUM 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.